Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Pancreatic Ductal Adenocarcinoma
Clinical trial register · Japan

Pancreatic Ductal Adenocarcinoma Trials in Japan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2517 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:19 UTC
2517
Studies in scope
all four open statuses
1288
Recruiting now
open to new participants
355
Lead sponsors
across recruiting studies
Top sites
Kashiwa 6 Nagoya 5 Osaka 4 Chiba 3 Tokyo 3
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Pancreatic Ductal Adenocarcinoma trials in Japan

13 of 2517 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
Hirakata, Koto-ku
2025-07-25
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Chūōku, Kashiwa, Kōtoku
2025-04-29
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Chiba, Kyoto, Shizuoka, Tokyo
2024-10-21
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
Chiba, Kanagawa, Nagoya, Osaka, Tokyo
2024-09-12
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Kashiwa, Yokohama
2024-06-20
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
Chūōku, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi
2023-12-13
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Kashiwa
2023-11-20
Recruiting
AbbVie
Phase 1
325
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-Ku, Koto-ku
2023-11-09
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
392
Chūōku, Kashiwa, Kōtoku
2023-07-11
Recruiting
Pancreatic Cancer Detection Consortium
NCT06388967Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
City of Hope Medical Center
Observational
2,000
Nagoya
2023-03-15
Recruiting
AB122 Platform Study
NCT04999761Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 1
917
Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo
2021-06-01
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-japan/condition/pancreatic-ductal-adenocarcinoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,517 studies in total at the last sync on 15 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Pancreatic Ductal Adenocarcinoma.

How many Pancreatic Ductal Adenocarcinoma trials are recruiting in Japan?

9 of the 13 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreatic Ductal Adenocarcinoma), 13 studies
PhaseStudiesRecruitingShare
Phase 16446.2%
Phase 1/23223.1%
Phase 22215.4%
Observational117.7%
Phase 2/3107.7%

Most active sponsors

Lead sponsors with the most studies (Pancreatic Ductal Adenocarcinoma)
Lead sponsorStudiesRecruiting
AstraZeneca32
AbbVie22
Eli Lilly and Company20
Astellas Pharma Inc11
Bristol-Myers Squibb10
City of Hope Medical Center11
Merck Sharp & Dohme LLC11
Seagen, a wholly owned subsidiary of Pfizer11
Taiho Pharmaceutical Co., Ltd.11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.